Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Arm,Multi-center,Phase II Clinical Trial of Combined Therapy for Orelabrutinib,Rituximab and Methotrexate(RMO)in Newly-diagnosed Primary Center Nervous System Lymphoma(PCNSL)

Next Previous
Trial Profile

A Single Arm,Multi-center,Phase II Clinical Trial of Combined Therapy for Orelabrutinib,Rituximab and Methotrexate(RMO)in Newly-diagnosed Primary Center Nervous System Lymphoma(PCNSL)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Methotrexate (Primary) ; Orelabrutinib (Primary) ; Rituximab (Primary)
  • Indications CNS cancer; Diffuse large B cell lymphoma
  • Focus Therapeutic Use

Most Recent Events

  • 09 Dec 2024 According to an InnoCare Pharma Media Release, preliminary efficacy data from this study were presented at the ongoing 66th American Society of Hematology (ASH) Annual Meeting.
  • 09 Dec 2024 Results presented in the InnoCare Pharma Media Release.
  • 27 Sep 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top